• Process Control’s Increasing Role in Biosimilar Approval

    Regulators are moving the comparability goalpost, shifting the burden of proof from massive clinical trials to deep process understanding. In this new landscape, the ability to define and control CPPs is the only way to ensure a biosimilar remains highly similar to its reference. Join Bioprocess Online’s Jon O’Connell for a virtual Q&A with experts...

  • Flexible Therapeutic Development: Balancing Speed, Cost, and Process

    Explore how KBI Biopharma delivers fast, cost-effective, and robust microbial protein process development, tailored for first-in-human (FIH, Phase I) programs and adaptable to each client’s needs for speed, cost, and performance. Learning Objectives: - Key considerations for microbial cell line, fermentation, and purification development for FIH - How milestones align from proof-of-concept to toxicology material...

    Free
  • LSX World Congress Europe

    Lisbon Lisbon, Portugal

    LSX World Europe (LSX Europe) is a leading life science fundraising and investment event, bringing innovators and investors together through strategic 1:1 meetings and targeted networking. Early-stage (Seed–Series B) biotech, medical device, diagnostics and digital health companies, including university spin-outs - join to secure investment and build collaborations. Active life science investors attend, looking for...

  • Avoiding Scale-Up Surprises: Applying AI and Rapid Prototyping to Media and Process Development

    As biologics grow more complex and development timelines continue to tighten, many teams could encounter manufacturability challenges related to decisions around media, process, and scalability made earlier in development. Traditional, sequential workflows may not always surface potential challenges until programs are already moving toward scale-up, which can limit flexibility. In this webinar, Thermo Fisher Scientific...

  • Why Open-Source Models Matter for Computational Drug Discovery

    AI is reshaping every industry—and drug discovery is no exception. Across targets, molecules, and data at massive scale, AI is becoming integral to how modern therapeutics are discovered and developed. This panel explores how foundational open‑source AI engines like OpenFold and Boltz are being used across the drug discovery workflow, from target discovery and validation...

    Free